A similar analysis with combined ATF‐1 data sets revealed the ability of AR‐42, but not GTx‐024 treatment, to significantly impact ATF‐1 target gene regulation in tumor‐bearing mice implicating AR‐42's ability to modulate ATF‐1 activation in its anti‐cachectic efficacy (Fig 7E and Appendix Fig S11). This evidence concerns the gene ATF1 and neoplasm.